company background image
XGN

Exagen NasdaqGM:XGN Stock Report

Last Price

US$2.69

Market Cap

US$43.7m

7D

-38.7%

1Y

-80.9%

Updated

27 Sep, 2022

Data

Company Financials +
XGN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

XGN Stock Overview

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States.

Exagen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Exagen
Historical stock prices
Current Share PriceUS$2.69
52 Week HighUS$14.85
52 Week LowUS$2.65
Beta1.03
1 Month Change-40.75%
3 Month Change-52.05%
1 Year Change-80.88%
3 Year Change-82.36%
5 Year Changen/a
Change since IPO-85.52%

Recent News & Updates

Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Market forces rained on the parade of Exagen Inc. ( NASDAQ:XGN ) shareholders today, when the analysts downgraded their...

Shareholder Returns

XGNUS BiotechsUS Market
7D-38.7%-3.3%-5.8%
1Y-80.9%-27.4%-22.1%

Return vs Industry: XGN underperformed the US Biotechs industry which returned -30.6% over the past year.

Return vs Market: XGN underperformed the US Market which returned -23.7% over the past year.

Price Volatility

Is XGN's price volatile compared to industry and market?
XGN volatility
XGN Average Weekly Movement12.3%
Biotechs Industry Average Movement11.0%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: XGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: XGN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2002221Fortunato Roccahttps://www.exagen.com

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.

Exagen Inc. Fundamentals Summary

How do Exagen's earnings and revenue compare to its market cap?
XGN fundamental statistics
Market CapUS$43.74m
Earnings (TTM)-US$37.81m
Revenue (TTM)US$44.30m

1.0x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XGN income statement (TTM)
RevenueUS$44.30m
Cost of RevenueUS$22.32m
Gross ProfitUS$21.98m
Other ExpensesUS$59.79m
Earnings-US$37.81m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.33
Gross Margin49.61%
Net Profit Margin-85.36%
Debt/Equity Ratio43.4%

How did XGN perform over the long term?

See historical performance and comparison